BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?